Equities analysts expect Opko Health Inc. (NASDAQ:OPK) to post $223.90 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Opko Health’s earnings. The highest sales estimate is $224.20 million and the lowest is $223.60 million. Opko Health reported sales of $263.69 million during the same quarter last year, which would suggest a negative year over year growth rate of 15.1%. The business is expected to report its next quarterly earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Opko Health will report full year sales of $895.35 million for the current fiscal year, with estimates ranging from $890.60 million to $900.10 million. For the next fiscal year, analysts anticipate that the company will post sales of $953.55 million, with estimates ranging from $920.20 million to $986.90 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.08). The company had revenue of $222.50 million during the quarter, compared to analysts’ expectations of $241.27 million. Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. The business’s quarterly revenue was down 12.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.08) EPS.

Several equities research analysts recently weighed in on OPK shares. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Tuesday, April 30th. Barrington Research restated a “buy” rating and set a $5.00 target price on shares of Opko Health in a research note on Thursday, February 28th. Finally, ValuEngine cut Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Opko Health currently has an average rating of “Buy” and a consensus price target of $9.25.

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were acquired at an average price of $1.99 per share, with a total value of $398,000.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $6,107,212.49. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard C. Pfenniger, Jr. bought 50,000 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was bought at an average cost of $2.05 per share, for a total transaction of $102,500.00. Following the acquisition, the director now owns 171,310 shares of the company’s stock, valued at approximately $351,185.50. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 2,108,250 shares of company stock worth $4,725,980. 42.25% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Opko Health by 1.4% in the 4th quarter. BlackRock Inc. now owns 30,276,662 shares of the biotechnology company’s stock valued at $91,133,000 after buying an additional 408,951 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after buying an additional 614,442 shares in the last quarter. Vanguard Group Inc increased its position in shares of Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after buying an additional 614,442 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Opko Health by 11.0% in the 1st quarter. Geode Capital Management LLC now owns 4,527,632 shares of the biotechnology company’s stock valued at $11,817,000 after buying an additional 449,235 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Opko Health by 25.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock valued at $15,363,000 after buying an additional 897,406 shares in the last quarter. 22.64% of the stock is currently owned by institutional investors and hedge funds.

Shares of OPK traded up $0.07 during midday trading on Friday, hitting $2.08. The company had a trading volume of 8,361,863 shares, compared to its average volume of 5,182,215. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.99 and a current ratio of 1.10. The stock has a market capitalization of $1.21 billion, a PE ratio of -8.32 and a beta of 1.81. Opko Health has a 1 year low of $1.92 and a 1 year high of $6.40.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Featured Article: Quick Ratio

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.